Premature (Early) Ejaculation
6
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation
Pelvic Floor Muscle Training With or Without Extracorporeal Magnetic Innervation for Premature Ejaculation
Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation
Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation
On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation